Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial

Patrick Loehrer, Michael Jiroutek, Seena Aisner, Joseph Aisner, Mark Green, Charles R. Thomas, Robert Livingston, David H. Johnson

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

BACKGROUND. Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide. The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. MEIHODS. From July 1995 through February 1997, 34 patients with advanced thymoma or thymic carcinoma were entered on trial to receive etoposide (75 mg/m2 on Days 1-4) ifosfamide (1.2 g/m2 on Days 1-4), and cisplatin (20 mg/m2 on Days 1-4). Cycles were repeated every 3 weeks for four total cycles. RESULTS. Among 28 evaluable patients (pathology review excluded 6 patients), there were no complete responses and 9 partial responses (complete and partial responses combined, 32%; 95% confidence interval, 16-52%). The median follow-up was 43 months (range, 12.8-52.3 months), the median duration of response was 11.9 months (range, < 1-26 months), and the median overall survival was 31.6 months. Based on Kaplan-Meier estimates, the 1-year and 2-year survival rates were 89% and 70%, respectively. The toxicity was predominantly myelosuppression. CONCLUSIONS. The VIP regimen has moderate activity in patients with advanced thymic malignancies. However, with limited follow-up, the results of this trial appear to be inferior to other chemotherapy regimens reported in large Phase II trials performed in patients with this disease.

Original languageEnglish
Pages (from-to)2010-2015
Number of pages6
JournalCancer
Volume91
Issue number11
DOIs
StatePublished - Jun 1 2001

Fingerprint

Ifosfamide
Thymoma
Etoposide
Cisplatin
Therapeutics
Thymus Neoplasms
Survival
Kaplan-Meier Estimate
Disease-Free Survival
Survival Rate
Confidence Intervals
Pathology
Drug Therapy

Keywords

  • Cisplatin
  • Etoposide
  • Ifosfamide
  • Thymic carcinoma
  • Thymoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial. / Loehrer, Patrick; Jiroutek, Michael; Aisner, Seena; Aisner, Joseph; Green, Mark; Thomas, Charles R.; Livingston, Robert; Johnson, David H.

In: Cancer, Vol. 91, No. 11, 01.06.2001, p. 2010-2015.

Research output: Contribution to journalArticle

Loehrer, Patrick ; Jiroutek, Michael ; Aisner, Seena ; Aisner, Joseph ; Green, Mark ; Thomas, Charles R. ; Livingston, Robert ; Johnson, David H. / Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial. In: Cancer. 2001 ; Vol. 91, No. 11. pp. 2010-2015.
@article{99154395f05a4bf1852c2cb22389d02a,
title = "Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial",
abstract = "BACKGROUND. Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide. The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. MEIHODS. From July 1995 through February 1997, 34 patients with advanced thymoma or thymic carcinoma were entered on trial to receive etoposide (75 mg/m2 on Days 1-4) ifosfamide (1.2 g/m2 on Days 1-4), and cisplatin (20 mg/m2 on Days 1-4). Cycles were repeated every 3 weeks for four total cycles. RESULTS. Among 28 evaluable patients (pathology review excluded 6 patients), there were no complete responses and 9 partial responses (complete and partial responses combined, 32{\%}; 95{\%} confidence interval, 16-52{\%}). The median follow-up was 43 months (range, 12.8-52.3 months), the median duration of response was 11.9 months (range, < 1-26 months), and the median overall survival was 31.6 months. Based on Kaplan-Meier estimates, the 1-year and 2-year survival rates were 89{\%} and 70{\%}, respectively. The toxicity was predominantly myelosuppression. CONCLUSIONS. The VIP regimen has moderate activity in patients with advanced thymic malignancies. However, with limited follow-up, the results of this trial appear to be inferior to other chemotherapy regimens reported in large Phase II trials performed in patients with this disease.",
keywords = "Cisplatin, Etoposide, Ifosfamide, Thymic carcinoma, Thymoma",
author = "Patrick Loehrer and Michael Jiroutek and Seena Aisner and Joseph Aisner and Mark Green and Thomas, {Charles R.} and Robert Livingston and Johnson, {David H.}",
year = "2001",
month = "6",
day = "1",
doi = "10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2",
language = "English",
volume = "91",
pages = "2010--2015",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial

AU - Loehrer, Patrick

AU - Jiroutek, Michael

AU - Aisner, Seena

AU - Aisner, Joseph

AU - Green, Mark

AU - Thomas, Charles R.

AU - Livingston, Robert

AU - Johnson, David H.

PY - 2001/6/1

Y1 - 2001/6/1

N2 - BACKGROUND. Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide. The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. MEIHODS. From July 1995 through February 1997, 34 patients with advanced thymoma or thymic carcinoma were entered on trial to receive etoposide (75 mg/m2 on Days 1-4) ifosfamide (1.2 g/m2 on Days 1-4), and cisplatin (20 mg/m2 on Days 1-4). Cycles were repeated every 3 weeks for four total cycles. RESULTS. Among 28 evaluable patients (pathology review excluded 6 patients), there were no complete responses and 9 partial responses (complete and partial responses combined, 32%; 95% confidence interval, 16-52%). The median follow-up was 43 months (range, 12.8-52.3 months), the median duration of response was 11.9 months (range, < 1-26 months), and the median overall survival was 31.6 months. Based on Kaplan-Meier estimates, the 1-year and 2-year survival rates were 89% and 70%, respectively. The toxicity was predominantly myelosuppression. CONCLUSIONS. The VIP regimen has moderate activity in patients with advanced thymic malignancies. However, with limited follow-up, the results of this trial appear to be inferior to other chemotherapy regimens reported in large Phase II trials performed in patients with this disease.

AB - BACKGROUND. Patients with thymic tumors (thymoma and thymic carcinoma) are known to respond to a variety of chemotherapeutic agents, including single-agent ifosfamide and cisplatin with etoposide. The purpose of this trial was to evaluate the response rate, progression free survival, overall survival, and toxicity of combined etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced thymoma and thymic carcinoma. MEIHODS. From July 1995 through February 1997, 34 patients with advanced thymoma or thymic carcinoma were entered on trial to receive etoposide (75 mg/m2 on Days 1-4) ifosfamide (1.2 g/m2 on Days 1-4), and cisplatin (20 mg/m2 on Days 1-4). Cycles were repeated every 3 weeks for four total cycles. RESULTS. Among 28 evaluable patients (pathology review excluded 6 patients), there were no complete responses and 9 partial responses (complete and partial responses combined, 32%; 95% confidence interval, 16-52%). The median follow-up was 43 months (range, 12.8-52.3 months), the median duration of response was 11.9 months (range, < 1-26 months), and the median overall survival was 31.6 months. Based on Kaplan-Meier estimates, the 1-year and 2-year survival rates were 89% and 70%, respectively. The toxicity was predominantly myelosuppression. CONCLUSIONS. The VIP regimen has moderate activity in patients with advanced thymic malignancies. However, with limited follow-up, the results of this trial appear to be inferior to other chemotherapy regimens reported in large Phase II trials performed in patients with this disease.

KW - Cisplatin

KW - Etoposide

KW - Ifosfamide

KW - Thymic carcinoma

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=0342468002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342468002&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2

DO - 10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2

M3 - Article

C2 - 11391579

AN - SCOPUS:0342468002

VL - 91

SP - 2010

EP - 2015

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -